NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2025年1月6日 - 9:55PM
ビジネスワイヤ(英語)
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, will attend the 43rd Annual J.P. Morgan
Healthcare Conference in San Francisco, California. Chris Smith,
Chief Executive Officer, will deliver a presentation followed by
Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET.
The presentation will be webcast live and accessible online via
this link. A replay will be available on the Investor Relations
section of the Company’s website at ir.neogenomics.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus for physicians to help them diagnose
and treat cancer. The Company’s Advanced Diagnostic Division also
serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250106693170/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
過去 株価チャート
から 12 2024 まで 1 2025
NeoGenomics (NASDAQ:NEO)
過去 株価チャート
から 1 2024 まで 1 2025